Sorrento Therapeutics Inc

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It operates through the Sorrento Therapeutics and Scilex segments. The Sorrento Therapeutics segment consists of developing a portfolio of next generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. The Scilex segment is largely organized around the company's non-opioid pain management operations. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

SRNE stock is up over 200% because the company is taking several bites at the Covid-19 apple. However time is not on the company's side.

Sorrento Therapeutics Is Simply Running Out of Time

Sorrento (SRNE) collaborates with ViralClear Pharmaceuticals to evaluate the combination of antibody and antiviral assets against COVID-19.

Sorrento & ViralClear Explore Combination Coronavirus Treatments

Sorrento's multi-pronged approach makes SRNE stock a compelling bet for investors looking to expand their portfolios. The post Sorrento’s Covid-19 Portfolio Makes It a Top Biotech Stock appeared first on InvestorPlace.

Sorrento’s Covid-19 Portfolio Makes It a Top Biotech Stock

The coronavirus could be the biotech's make-or-break event.

17 Reasons to Be Excited About Sorrento Therapeutics and 1 Big Reason to Be Very Worried

WESTPORT, Conn., Sept. 30, 2020 (GLOBE NEWSWIRE) -- ViralClear Pharmaceuticals, Inc. (Nasdaq BSGM) and Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced the companies are exploring the synergistic potential of small molecules and antibodies combination therapies against COVID-19.

Sorrento Therapeutics and ViralClear Enter Into Agreement to Explore Combination Antibody Plus Antiviral Therapy Against COVID-19

Investors like the biotech's promising preclinical data for two experimental COVID-19 antibody therapies.

Why Sorrento Therapeutics Stock Is Surging Today

Sorrento Therapeutics Inc (NASDAQ: SRNE) shares are rising again following gains in the previous two sessions.
 What Happened:  San Diego, California-based Sorrento, which is developing antibody treatments against SARS-CoV-2, said preclinical data showed its COVI-GUARD and COVI-AMG antibodies demonstrated potent neutralizing activities against the virus that caused COVID-19.

Sorrento Identifies Second 'More Potent' Anti-COVID-19 Antibody For Clinical Testing

SAN DIEGO, Sept.  28, 2020  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) released preclinical data reporting on COVI-GUARD™ (STI-1499) and COVI-AMG™ (STI-2020;  A ffinity  M atured COVI- G uard) neutralizing antibodies (nAbs) against SARS-CoV-2 as well as a D614G virus variant infection in a preprint publication, which can be found at {https://biorxiv.org/cgi/content/short/2020.09.27.316174v1}. Both STI-1499 and STI-2020 demonstrated potent neutralizing activities against SARS-CoV-2 virus infection in preclinical models. STI-1499 nAb has been cleared by the FDA for a Phase 1 clinical trial in hospitalized COVID-19 patients. STI-2020 is an affinity-matured version of the COVI-GUARD nAb and has demonstrated a greater than 50-fold increase in potency in in vitro experiments.

Sorrento Releases Preclinical Data for STI-1499 (COVI-Guard™) and STI-2020 (COVI-AMG™), Potent Neutralizing Antibodies Against SARS-CoV-2

SAN DIEGO, Sept.  28, 2020  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") released positive Phase 1b trial data (clinicaltrials.gov NCT03542838) of resiniferatoxin (RTX) with completed Day 84 effectiveness data (end-point analysis) for all patients and completed six-month follow-ups in all doses for all patients enrolled, with no negative safety signal as of September 2020.

Sorrento Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) In Reduction of OsteoArthritis (OA) Knee Pain

It's a great time to be long SRNE stock as the company's ambitious Covid-19 treatment clinical trials take a giant step forward for Sorrento.
The post FDA Clearance Means It’s Go Time for Sorrento Therapeutics appeared first on InvestorPlace.

FDA Clearance Means It’s Go Time for Sorrento Therapeutics

Bears are waging a heavy and crowded bet against SRNE stock, but more good news could send the stock higher.
The post Why Investors Should Take a Serious, Bullish Look on Sorrento appeared first on InvestorPlace.

Why Investors Should Take a Serious, Bullish Look on Sorrento

Investors need to pay close attention to Sorrento (SRNE) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Sorrento (SRNE) Stock?

SRNE stock can benefit from multiple efforts in the fight against the novel coronavirus. Risks are real, but the rewards are as well.

FDA Approval Highlights High-Risk Case for Sorrento Therapeutics Stock

Adaptimmune Therapeutics

Chemocentryx

Kodiak Sciences Inc

Seres Therapeutics

Myovant Sciences

Novavax

The pandemic has raised awareness about the value of biotech across the world. In turn, these biotech stocks will benefit down the road.

7 ‘A-Rated’ Aggressive Biotech Stocks to Gamble On

SAN DIEGO, Sept.  22, 2020  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced the public release of the results of its’ multicenter, open-label, Phase 1b Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for the Treatment of Intractable Cancer Pain, at the 14th Annual Pain Therapeutics Summit held virtually from September 21 to 22, 2020. Data was presented by Srdjan Nedeljkovic, MD, Associate Professor of Anesthesia, Harvard Medical School/Brigham & Women's Hospital.

Sorrento Therapeutics Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) Epidural in Cancer Patients with Reported Intractable Pain

So, what's the call here? If you have a high risk tolerance, and are looking for a short-term pandemic play, SRNE stock today may be worth the risk.

Tread Carefully, But Sorrento Stock Could Continue to Bounce Back

Despite a massive 5x rise since the March 23 lows of this year, at the current price of around $9 per share we believe Sorrento Therapeutics stock has more room for growth. SRNE stock shot up 13% in Thursday’s trade owing to the U.S.

Sorrento Therapeutics Stock Is An Interesting Pick At $9

Sorrento (SRNE) receives an FDA clearance to begin a phase I study on STI-1499 (COVI-GUARD) for treating hospitalized COVID-19 patients. Shares rise.

Sorrento Gets FDA Nod for Phase I Study on Coronavirus Antibody

Sorrento has some potential positive catalysts, especially its Covid-19 diagnostic test. But SRNE stock is really just for the speculative part of your portfolio.

Is Sorrento Stock Really Worth the Speculation?

Lack of a track record, a lagging Covid-19 test project and executive turmoil make SRNE stock a coronavirus play to avoid.
The post Sorrento Therapeutics Fails the Test as a Covid-19 Value Play appeared first on InvestorPlace.

Sorrento Therapeutics Fails the Test as a Covid-19 Value Play

Ebang International Holdings

Penn Entertainment

Vaxart

Not all penny stocks are worth your time but a proper strategy can keep you in winning trades longer.

5 Penny Stocks That Were Home Runs In 2020

Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares jumped on Thursday after the company announced that it received approval from the U.S.

Sorrento Therapeutics Wins FDA Approval to Proceed With COVID-19 Study

Sorrento Therapeutics Inc (NASDAQ: SRNE) shares, which are known for being volatile, are headed higher Thursday morning.

Sorrento Surges On FDA Nod For Initiating Clinical Study Of COVID-19 Antibody Treatment

Sorrento Therapeutics just announced plans to launch human trials of its antibody drug. Here's why else SRNE stock is rallying.

SRNE Stock: Sorrento Therapeutics Pops on Plans to Launch Drug Trials

SAN DIEGO, Sept.  16, 2020  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it received a study may proceed letter from the FDA for its phase 1 clinical trial for COVI-GUARD (STI-1499) in hospitalized COVID-19 patients.

News for Sorrento Therapeutics Inc Stock (SRNE)